Main Session
Sep 27
QP 03 - Right Care, Right Cost: Access and Utilization in Oncology

1012 - The Cost Effectiveness of Neoadjuvant FOLFIRINOX vs. Gemcitabine Based Chemoradiotherapy (CRT) for Resectable or Borderline-Resectable Pancreatic Ductal Adenocarcinoma

05:05pm - 05:10pm ET

Presenter(s)

Nandita Kasireddy, - Geisel School of Medicine at Dartmouth, Lebanon, WA